# Reveragen Biopharma Inc. – FDA Inspection, Mar 6, 2023

Source: https://www.keypedia.com/records/fda_inspections/reveragen-biopharma-inc/7b9c6294-f474-42d7-8a48-9f7b86f9126d
Source feed: FDA_Inspections

> FDA inspection 1199304 of Reveragen Biopharma Inc., March 06, 2023. Classification: Voluntary Action Indicated (VAI). 4 citations under 21 CFR part 312. Form 483 issued.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1199304
- Company Name: Reveragen Biopharma Inc.
- Inspection Date: 2023-03-06
- Classification: Voluntary Action Indicated (VAI)
- Classification Code: VAI
- Project Area: Bioresearch Monitoring
- Product Type: Drugs
- Center: Human Drugs
- Office Name: Center for Drug Evaluation and Research
- Citation Count: 4

## Related Officers

- [Investigator](https://www.keypedia.com/people/david-l-chon/227b9c21-14c4-442b-bdc3-ad167567fd92)
- [Issuing Officer](https://www.keypedia.com/people/glenn-b-mannheim/214abb55-60b0-497f-a588-6ef3a42dd2da)

Company: https://www.keypedia.com/companies/reveragen-biopharma-inc/eaf70eaf-05c9-4025-b737-094553dcf19f

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c